- ¥2980
- LMAI Bio
- LM-11336R-FITC
- 中国/美国/欧洲
- 2025年07月11日
- 详见说明书
- Human, Mouse, Rat,
- Human, Mouse, Rat,
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
上海联迈生物工程有限公司
- 库存：
大量
- 靶点：
详见说明书
- 级别：
1
- 目录编号：
LM-11336R-FITC
- 克隆性：
多克隆
- 抗原来源：
Rabbit
- 保质期：
1年
- 抗体英文名：
Anti-C1Q/FITC
- 抗体名：
Anti-C1Q/FITC
- 标记物：
FITC标记
- 宿主：
Human, Mouse, Rat,
- 适应物种：
Human, Mouse, Rat,
- 免疫原：
详见说明书
- 亚型：
IGg
- 形态：
粉末、液体、冻干粉
- 应用范围：
详见说明书
- 浓度：
1mg/ml
- 保存条件：
-20 °C
- 规格：
100ul
| 英文名称 | Anti-C1Q/FITC |
| 中文名称 | FITC标记的补体C1qα链多肽抗体 |
| 别 名 | C1QA; C1QA_HUMAN; C1QB; C1QC; Complement C1q subcomponent subunit A; Complement C1q subcomponent subunit B; Complement C1q subcomponent subunit C; Complement component 1 q subcomponent A chain; Complement component 1 q subcomponent alpha polypeptide; Complement component C1q A chain; Complement component C1q B chain; Complement component C1q C chain. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 免疫学 神经生物学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, |
| 产品应用 | not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 24kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human C1QA |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: C1q, a subcomponent of the classical complement pathway, is composed of nine subunits that mediate classical complement activation and thereby play an important role in the immune response. Six of these subunits are disulfide-linked dimers of chains A and B, while three of these subunits, designated C1q-A through C1q-C, are disulfide-linked dimers of chain C. The presence of receptors for C1q on effector cells modulates its activity, which may be antibody-dependent or independent. Macrophages are the primary source of C1q, while anti-inflammatory drugs as well as cytokines differentially regulate expression of the mRNA as well as the protein. However, its ability to modulate the interaction of platelets with collagen and immune complexes suggests C1q influences homeostasis as well as other immune activities, and perhaps thrombotic complications resulting from immune injury. Defects in C1q-A, C1q-B and C1q-C cause inactivation of the classical pathway, leading to a rare genetic disorder characterized by lupus-like symptoms. Function: C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes. Subunit: C1 is a calcium-dependent trimolecular complex of C1q, R and S in the molar ration of 1:2:2. C1q subcomponent is composed of nine subunits, six of which are disulfide-linked dimers of the A and B chains, and three of which are disulfide-linked dimers of the C chain. Subcellular Location: Secreted. Post-translational modifications: O-linked glycans consist of Glc-Gal disaccharides bound to the oxygen atom of post-translationally added hydroxyl groups. DISEASE: Defects in C1QA are the cause of complement component C1qA deficiency (C1QAD) [MIM:120550]. A rare defect resulting in C1 deficiency and impaired activation of the complement classical pathway. C1 deficiency generally leads to severe immune complex disease with features of systemic lupus erythematosus and glomerulonephritis. Similarity: Contains 1 C1q domain. Contains 1 collagen-like domain. Database links: Entrez Gene: 712 Human Entrez Gene: 12259 Mouse Entrez Gene: 29687 Rat Omim: 120550 Human SwissProt: P02745 Human SwissProt: P14106 Mouse SwissProt: P31720 Rat Unigene: 632379 Human Unigene: 439957 Mouse Unigene: 105647 Rat
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相联在一起，同时C1r还是C1q和C1s的联桥。C1s是一种α2球蛋白，单链，可被C1r激活，医学教育|网搜集整理C1s具有酶样活性，在Mg2+存在时激活C4和C2。 2.C4 是一种β球蛋白，由3条多肽链组成（α，β，γ），分子量分别是95kD、78kD和33kD.C1s可将3条链中最大的α链裂解，释放出一较小的多肽C4a，余下的大部分结合在靶细胞上，进行补体的下一步活化程序。 3.C2 是一种β球蛋白，单链，是血清中含量最少的补体成分。激活的C2极不稳定，易衰变，形成补体系统中的一种自身调节
经典途径 经典途径是以结合抗原后的IgG或IgM类抗体为主要激活剂，补体C1～C9共11种成分全部参与的激活途径。现发现除抗原抗体复合物外，还有许多因子可激活此途径，如非特异性凝集的Ig、细菌脂多糖、一些RNA肿瘤病毒、双链DNA、胰蛋白酶、纤溶酶、尿酸盐结晶、C-反应蛋白等。经典活化途径可人为地分成识别、活化和膜攻击3个阶段。 1.识别阶段在抗体结合抗原形成复合物后，与C1q结合。IgG1、IgG2、IgG3的补体结合位点在CH2区内，而IgM补体结合位点在CH3区内，IgG
结合抗原形成复合物后，与C1q结合。IgG1、IgG2、IgG3的补体结合位点在CH2区内，而IgM补体结合位点在CH3区内，IgG4、IgA、IgD和IgE不能结合补体。电镜下观察发现，C1q的球形结构与抗体结合后，进一步激活C1r和C1s，C1s具有酯酶活性，继之进入下一步的连续反应。研究还发现激活C1q的球形分子必须具有2个以上紧密相邻的IgG分子，IgM只需1分子即可，故单分子IgM比IgG激活补体的能力大得多，在补体介导的抗体溶细胞反应中，同量的IgM比IgG更有效。 2.活化阶段此阶段主要
技术资料暂无技术资料 索取技术资料
